What the EU Joint Clinical Assessment Means for Patient Support Programs in 2026

For most pharmaceutical commercial and patient engagement teams, the EU Joint Clinical Assessment has so far seemed like a regulatory problem handled by market access and HEOR specialists (health economics and outcomes research) who work on dossiers and complex evidence frameworks. That perception is changing rapidly, and for good reason. The JCA does not just raise the bar for clinical evidence. It fundamentally changes what kind of data pharmaceutical companies need, when they need it, and where it has to come from. Patient support programs and the digital platforms that power them are now at the center of this evidence question in an entirely new way.

The regulation most patient support teams still underestimate

The EU Health Technology Assessment Regulation, HTA Regulation for short, formally Regulation (EU) 2021/2282, entered into force in January 2022 and has applied since January 12, 2025. Since then, all new cancer medicines and advanced therapy medicinal products have had to undergo a Joint Clinical Assessment at EU level before individual member states make their own national pricing and reimbursement decisions. The regulation will be extended to medicines for rare diseases in January 2028 and is set to cover all newly authorized medicines by 2030. From 2026, selected high-risk medical devices are also being included for the first time.

The JCA is a centralized, EU-wide assessment of the relative clinical effectiveness and safety of a health technology compared with existing alternatives. It runs in parallel with the approval procedure of the European Medicines Agency (EMA) and produces a single, standardized clinical assessment report that all 27 member states can draw on for their national reimbursement decisions. The aim is to avoid duplication of work between member states, accelerate patient access to innovative therapies, and introduce a more consistent and transparent standard of evidence assessment across Europe.

An important clarification that is crucial for how patient support teams understand the JCA: the JCA focuses exclusively on clinical domains. It does not make value judgments, economic evaluations, or reimbursement decisions. Those decisions remain the responsibility of the individual member states. What the JCA provides is a shared clinical foundation that feeds into downstream national HTA processes and payer negotiations. Patient-generated data from support programs therefore flows into these downstream national processes, and that is where pricing, reimbursement, and access outcomes are ultimately determined.

What makes this so significant for patient support teams is what the JCA and the downstream national HTAs now require together. Whereas individual national HTAs previously assessed a product against a single comparator in a defined patient group, manufacturers must now address a much broader set of evidence requirements structured around so-called PICO frameworks. PICO stands for Population, Intervention, Comparator, and Outcomes, that is, the patient group, the treatment, the comparator therapy, and the relevant outcomes. These frameworks cover multiple patient groups, multiple comparators, and a broader range of clinical outcomes at the same time in order to meet the differing evidence needs of all 27 member states. All of this has to be addressed within around 100 days of the consolidated PICO list being transmitted for standard procedures, and in just 60 days for accelerated EMA procedures. Manufacturers cannot wait for the official PICO list before starting their evidence work. They need to get going early on the basis of anticipated requirements, or they risk a public statement about missing evidence in the final JCA report.

The evidence gap nobody planned for

Clinical trial data alone is no longer enough to meet the combined requirements of the JCA and the downstream national HTA processes. This is not a matter of opinion; it is becoming increasingly visible in the first real assessments moving through the system.

The JCA calls for outcomes that go beyond what the EMA requires for marketing authorization. Member states regularly request evidence on patients' quality of life, health-related quality of life trajectories, and patient-relevant endpoints such as symptom burden and everyday functioning, alongside the traditional clinical efficacy and safety endpoints. Research published in the journal Pharmaceutical Medicine has confirmed that the JCA framework introduces requirements that vary considerably between member states, with different countries placing different weight on surrogate endpoints, patient-reported outcomes, and quality of life measures.

Germany's AMNOG process, which stands for Arzneimittelmarktneuordnungsgesetz, the German Pharmaceutical Market Restructuring Act, runs in coordination with the JCA and governs how new medicines are assessed for their added benefit before a reimbursement price is negotiated. The Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA), which oversees the AMNOG process, requires claimed benefits to be validated against patient-relevant endpoints such as survival, morbidity, and health-related quality of life. The 2024 revision of the Module 3 dossier requirements placed further emphasis on the role of real-world evidence in determining target population size and treatment patterns. An analysis presented at ISPOR Europe 2025 confirmed that 66.7 percent of AMNOG dossiers submitted under the new requirements included real-world evidence, a significant shift away from the earlier reliance on clinical trial data alone.

France's Haute Autorité de Santé (HAS) and Scotland's Scottish Medicines Consortium (SMC) are similarly asking more critical questions about whether clinical trial results actually translate into meaningful outcomes for real patients in real-world care. The pattern across European HTA bodies is clear: randomized controlled trial data shows that a therapy can work, but it is the patient experience in the real world, captured longitudinally and in a structured way, that increasingly determines how much a therapy is worth and how broadly it is reimbursed at national level.

Why this is now a patient support problem too

The evidence gap exposed by the JCA cannot be closed by market access teams alone through dossier work. It requires data that comes from patients living with their therapy over an extended period, data that describes what actually happens when a medicine leaves the controlled environment of a clinical trial and enters everyday life.

This is where patient support programs become strategically relevant in a genuinely new way. Until now, they have mainly been designed and evaluated on the basis of adherence and persistence outcomes, sometimes also in terms of their effect on prescriber satisfaction, and occasionally for their role in capturing adverse events. The national HTA processes that follow the JCA change this starting point considerably.

Patients who are enrolled in a well-designed digital support program from the moment of their first prescription generate, over months and years of engagement, exactly the kind of longitudinal patient-reported data that national HTA bodies are increasingly looking for. Adherence patterns, side effect experiences, quality of life trajectories, symptom burden over time, treatment satisfaction scores, and everyday functioning are data points that are typically not captured in clinical trials, yet they are precisely what downstream national HTAs and payer negotiations increasingly require as part of the evidence base for pricing and reimbursement decisions.

A study published in PLOS ONE in 2024, involving researchers from Novartis Ireland and Novartis Pharma GmbH, confirmed that patient support programs are a significant and so far underused source of real-world data on medication use, adherence, and patient experience. The study concluded that the potential of this data for regulatory and HTA purposes remains largely untapped because of gaps in how data is collected, structured, and managed. This is an honest assessment of the current state, and it points directly to where both the opportunity and the challenge lie.

The honest truth about patient support data and what it takes to make it credible

This is the part of the conversation that deserves real candor, because the gap between what patient support programs currently produce and what HTA bodies will actually accept is considerable and should not be glossed over.

European HTA bodies and decision-makers in regulatory and reimbursement processes have so far treated data from patient support programs as low-level evidence. The concerns are well documented. This type of data is collected by or on behalf of the manufacturer, which creates a perception of bias that even high-quality data can hardly overcome without independent validation. Data governance varies enormously from program to program. Collection methods are often designed for patient management purposes rather than for scientific rigor. And the absence of prospective analysis plans has historically made it difficult to use patient support data credibly in formal submissions.

These are structural problems, not merely problems of perception. A study published in PMC in 2025 that examined Canadian patient support program data against guidelines for real-world evidence was unequivocal on this point: regulatory and HTA bodies currently regard this type of data as low-level evidence, and a lack of public transparency about how programs operate remains a central problem.

The important point is that these problems are solvable, but only if they are addressed from the very start of designing a patient support program, not retrospectively once the access question has already become urgent. A digital patient support platform that is built with standardized, scientifically validated instruments for patient-reported outcomes (PROs), that is, structured questionnaires that capture patients' own assessment of their health, their symptoms, and their quality of life, and that at the same time offers GDPR-compliant data governance, pseudonymized and structured data collection, and the ability to deploy indication-specific question sets within a consistent methodological framework, is a fundamentally different evidence asset from a platform designed primarily to generate engagement metrics. The former has a credible path to contributing to national HTA submissions downstream of the JCA. The latter does not.

This is the distinction that is now commercially decisive. Pharmaceutical companies that design their patient support infrastructure with evidence generation requirements built in from the outset are building something that can actually influence national pricing and reimbursement discussions. Those that do not are generating data that the payers and HTA bodies deciding on market access outcomes will hardly take seriously.

What the JCA timeline means for evidence planning now

One of the most important and least understood effects of the JCA on patient support teams is the timeline problem. The JCA process runs in parallel with the EMA approval procedure, which means that manufacturers have to manage their marketing authorization submission, their JCA dossier preparation, and their national HTA preparations in 27 member states simultaneously, all within timeframes that leave no room for reactive evidence generation.

The 100-day window for standard procedures, which is reduced to just 60 days for accelerated procedures, creates an evidence generation challenge that can no longer be met at the time of launch. Evidence that is meant to feed into downstream national HTA processes after the JCA has to be built during the clinical development phase or, at the latest, from the time of the marketing authorization submission, not only after the PICO list has arrived.

This means that for products in late-stage development or shortly after launch, the window for building a meaningful real-world evidence base from patient engagement is open now, but it will not stay open indefinitely. Companies that only start patient support programs after marketing authorization and then try to generate longitudinal evidence from scratch are working against a timeline that the JCA environment makes extremely difficult to manage.

The companies best positioned for national HTA submissions over the next three to five years are those that start structured patient engagement and data collection early enough to have meaningful longitudinal datasets ready when they are needed. For products already in the post-launch phase, building this infrastructure is already an urgent priority.

The patient experience dimension that is easily overlooked

There is another aspect of the JCA that receives less attention but is of great importance. The JCA framework explicitly involves patients and clinical experts in the PICO scoping process. In practice, this means that patient-relevant outcomes that speak to quality of life, symptom burden, and everyday functioning are increasingly finding their way into the PICO frameworks that manufacturers have to address.

EURORDIS, the European patient organization for rare diseases, has described the regulation as an important milestone for European healthcare that promises fairer and more patient-centered decision-making. The extent to which this promise is fulfilled depends largely on whether the industry can generate patient experience data credible enough to be taken seriously by national HTA bodies and payers in the assessments that follow the JCA. This is precisely the kind of data that long-term digital patient engagement, properly designed and managed, is able to generate.

What pharma teams should do differently today

The JCA does not require a complete reinvention of patient support strategy, but it does require a significant expansion of how these programs are designed, managed, and evaluated.

Patient support programs must be designed from the outset with standardized, validated PRO instruments, and the choice of instruments should be informed by the PICO frameworks likely to be relevant for each product. This means bringing HEOR and market access teams into conversations about patient support program design that have so far mainly been the domain of commercial and patient services teams.

The digital platform through which patient support is delivered must be capable of generating structured, traceable, longitudinal data at scale. Independent data governance, transparent analysis plans, and pseudonymized data collection are not optional extras if the goal is to produce evidence that national HTA bodies will take seriously.

Patient support needs to be deployed earlier in the product life cycle. Starting meaningful digital patient engagement at or before the marketing authorization submission is no longer just good commercial practice; for products subject to the JCA, it is a strategic necessity for evidence generation.

And cross-functional collaboration between patient support, market access, HEOR, and medical affairs is now essential. The JCA has created a shared evidence challenge that cannot be solved within any single function.

The commercial opportunity in regulatory pressure

It would be easy to view all of this as nothing more than a burden. That view, however, misses the real commercial opportunity that the regulation creates for companies that approach it thoughtfully.

For the first time, the JCA will produce a single pan-European clinical assessment that informs reimbursement decisions in all 27 member states at once. The national pricing and reimbursement negotiations that follow will be shaped by the quality and completeness of the real-world evidence that manufacturers are able to present. A company that enters these national processes with credible, longitudinal, patient-generated data documenting real-world effectiveness, impact on quality of life, and treatment experience is in a much stronger negotiating position than one that arrives with clinical trial data alone.

This is exactly the evidence infrastructure that has been built with brite. In collaboration with the PROMIS Institute at Charité Berlin, one of Europe's leading research institutes for patient-centered outcomes research, XO Life has developed standardized PRO questionnaires that meet the scientific rigor required for credible evidence generation. The data collected via brite is pseudonymized, structured, and standardized. The platform is GDPR-compliant and scientifically validated, and pharma partners can deploy product-specific or indication-specific question sets within the same consistent methodological framework. It is not a patient engagement tool with evidence generation added as an afterthought, but a platform designed from the ground up to generate the kind of structured, high-quality patient-reported data that national HTA processes downstream of the JCA increasingly require.

The pharmaceutical companies that invest now in patient support infrastructure that generates evidence national HTA bodies will take seriously are not just preparing for a regulatory challenge. They are building a commercial asset that will influence pricing and access outcomes in every European market where JCA results feed into national reimbursement decisions, which from 2030 will mean every major European market for every new medicine. The window for building this asset is open. The question is simply who moves first.

Learn how brite helps pharmaceutical companies build patient relationships that generate real-world evidence at britehealth.com/en-de/partner/pharma